Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

Antengene presented at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, sharing latest data on core asset ATG-022 (CLDN18.2 ADC), showing improved ORR and mPFS at 1.8 mg/kg dose with 19.4% Grade 3+ TRAEs, positioning it for frontline combinations.1 2 3

ATG-125 (B7-H3 x PD-L1 bispecific ADC) preclinical studies show superior efficacy; IND planned for Q1 2027.1 2

AnTenGager™ TCE platform features steric hindrance masking, '2+1' binding, and optimized CD3 for reduced CRS; programs include ATG-201 (IND prep), ATG-106 (IND H1 2027), ATG-112 (PCC nominated Jan 2026), ATG-110 (IND H1 2027).1 3

ATG-207, first-in-class dual-function biologic for T cell-mediated autoimmune diseases, preclinical data to be presented at 2026 conference.1 2

Sources:

1. https://www.prnewswire.com/news-releases/antengene-presents-at-jpm-strong-clinical-data-update-and-strategic-focus-on-next-generation-adcs-and-tces-302662551.html

2. https://intellectia.ai/news/stock/antengene-corporation-presents-latest-data-on-atg022-at-jp-morgan-conference

3. https://www.marketscreener.com/news/antengene-corporation-limited-presents-strong-clinical-data-update-and-strategic-focus-on-next-gener-ce7e58deda8bf525

Sources:

Leave a Reply Cancel reply